Introduction {#S6}
============

The hemostatic system ensures the delicate balance between clotting and bleeding. Disturbance of this balance towards clotting may lead to venous thrombosis (VT), mainly manifested as pulmonary embolism (PE) or deep vein thrombosis (DVT) \[[@R1],[@R2]\]. Abnormal levels of both fibrinolytic and coagulation factors have been associated with VT risk \[[@R3]--[@R6]\]. The role of platelets as a risk factor is less well studied, with conflicting results being reported for associations between VT and several platelet markers \[[@R7],[@R8]\]. In addition, genetic variants, predominantly in genes encoding proteins of the hemostatic system, have been linked to VT risk \[[@R9]\]. Deficiencies of the natural anticoagulants antithrombin, protein C and protein S were among the first identified genetic causes of VT, and hundreds of (mainly rare) mutations have since been reported \[[@R10]\]. Two recent meta-analyses of genome-wide association studies (GWASs), each including \> 6000 patients and a multifold of controls, confirmed the association of six loci and identified three novel loci \[[@R11],[@R12]\]. The established loci all map to genes related to hemostasis, specifically: *F5, FGG, F11, ABO, F2,* and *PROCR* \[[@R9]--[@R12]\]. Two of the novel loci *(TSPAN15* and *SLC44A2),* and potentially a third locus at *HIVEP1* identified in an earlier GWAS \[[@R13]\] but not confirmed in the latest meta-analyses \[[@R11],[@R12]\], are the only replicated loci not directly connected to the hemostatic system. This suggests that genes regulating (components of) the hemostatic system are the main genetic contributors to VT risk.

Although VT has a strong genetic basis, with heritability estimates of 50--60% \[[@R14]--[@R16]\], the established genetic risk factors explain only a small proportion of the phenotypic variance \[[@R17]\]. In addition, the genetic component remains unknown in 30% of families with multiple family members affected by VT \[[@R18]\]. GWAS efforts have had limited success in identifying novel genetic risk factors, which were mainly common variants in hemostatis-related genes with small effects on VT risk. Therefore, a focus on rare and low-frequency variants in coding regions of the genome may help to discover novel determinants of VT. In this respect, we have previously shown that a burden of rare coding *ADAMTS13* variants is associated with a 4.8-fold increased DVT risk \[[@R19]\].

To extend the GWAS efforts, we performed targeted DNA sequencing of the coding regions of 734 genes that were or could be related to the hemostatic system in 899 DVT patients and 599 controls. We subsequently sought replication for associated variants by using meta-analysis data from the International Network against Thrombosis (INVENT) consortium \[[@R11]\].

Patients and methods {#S7}
====================

Study population {#S8}
----------------

We set up the Milan Leiden Sequencing study (MILES), in which we included patients with a first VT and controls without a history of VT from three population-based case--control studies: DVT-Milan, Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA), and the Thrombophilia, Hypercoagulability and Environmental Risks in Venous Thromboembolism (THE-VTE) study. All studies have been previously described in detail \[[@R19]--[@R21]\]. Briefly, DVT-Milan recruited 2139 consecutive patients with a first DVT at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center in Milan (Italy) between 1995 and 2010 \[[@R19]\]. Controls were non-consanguineous relatives, partners, or friends who accompanied patients to center visits. In MEGA, 4956 consecutive patients with a first DVT or PE were recruited at six anticoagulation clinics in the Netherlands between 1999 and 2004 \[[@R20]\]. Partners of patients were invited to participate as control subjects. Additional controls were recruited from the general population by the use of random digit dialing. Patients and controls were invited to provide a blood sample up to 2002, after which we switched, for logistical reasons, to buccal swabs. The THE-VTE study is a two-center case--control study with a similar design as MEGA, in which 796 consecutive patients with a first DVT or PE and 531 controls were enrolled in Leiden (the Netherlands) and Cambridge (UK) between 2003 and 2008 \[[@R21]\]. Again, partners of eligible patients were invited to participate as controls.

From each study, we included patients and controls on the basis of the following criteria: high-quality DNA sample available from blood, European ancestry as defined by self-reported country of birth of the parents, no major surgery or cancer diagnosis related to the index date, and no deficiency of the natural anticoagulant proteins, defined as having normal levels of protein C, protein S, and antithrombin. To eliminate two major genetic causes of VT, we included patients and controls who did not carry factor V (FV) Leiden (rs6025) or prothrombin (PT) G20210A (rs1799963). In addition, we oversampled patients who had a recurrence during the follow-up studies of MEGA and the THE-VTE study (*N* = 241), as these are more likely to carry genetic risk factors for VT. To ensure a sufficient sample size, we allowed recurrent VT patients to carry FV Leiden or PT G20210A *(N* = 94). In total, 899 DVT patients and 599 controls were selected for sequencing. An overview of the participants per study is shown in [Table S1](#SD1){ref-type="supplementary-material"}.

All participants provided written informed consent. DVT-Milan was approved by the Institutional Review Board of the Fondazione IRCCS Ca' Granda--Ospedale Maggiore Policlinico, whereas MEGA and the THE-VTE study were approved by the Medical Ethics Committee of the Leiden University Medical Center. The THE-VTE study was also approved by the National Health Service Research Ethics Committee in Cambridge.

Targeted DNA sequencing {#S9}
-----------------------

We selected pathways involved in thrombosis and hemostasis, including the coagulation system, fibrinolysis, platelet function, inflammation, and the complement system. Using literature and gene ontology databases, we extracted genes belonging to these pathways. From the ThromboGenomics database \[[@R22]\], we included additional genes that have been linked to inherited clotting, platelets, or bleeding disorders. In total, we included 734 genes, and sequenced the coding regions plus 10 bp flanking the exons to cover the splice junctions. For a subset of 48 genes, we additionally sequenced the 3'-untranslated region (UTR) and the 5'-UTR. In addition, we performed whole gene sequencing including the 10-kbp promoter areas of three genes, i.e. *F5, VWF,* and *F8,* which are of particular interest for VT. *F5* harbors the strongest genetic risk factor for VT, i.e. FV Leiden, in the general population. Von Willebrand factor and FVIII, encoded by *VWF* and *F8,* are tightly interconnected proteins whose levels are strongly associated with first and recurrent VT risk \[[@R5],[@R23]\]. We also targeted 179 single-nucleotide variants, consisting of 28 variants previously associated with VT and 151 ancestry-informative markers. To facilitate the capture, we allowed some 200 bp of target region surrounding each variant. A list of the targeted genes and variants is shown in [Table S2](#SD1){ref-type="supplementary-material"}.

The target area was designed with the Reference Sequence (RefSeq) Database by the use of tools in the University of California Santa Cruz Genome Browser \[[@R24]\], and sent to NimbleGen (Roche NimbleGen, Madison, WI, USA) for probe design. Next-generation DNA sequencing was subsequently performed at the Human Genome Sequencing Center (HGSC), Baylor College of Medicine (Houston, TX, USA). A complete sequencing protocol can be accessed on the HGSC website (<https://www.hgsc.bcm.edu/content/protocols-sequencing-library-construction>). Briefly, Illumina paired-end pre-capture libraries were constructed from extract DNA according to the manufacturer's protocol (Illumina Multiplexing_SamplePrep_Guide_1005361_D) with some minor modifications. We multiplexed 24 samples per capture, and included two capture pools per HiSeq lane. Enriched samples were sequenced with the HiSeq 2000 platform (Illumina, San Diego, CA, USA).

Sequence analysis was performed with the MERCURY analysis pipeline \[[@R25]\]. In short, sequence reads and basecall confidence values were generated for demultiplexed pools with the vendor's primary analysis software (CASAVA). Next, reads and qualities were mapped to reference genome hg19 by use of the Burrows--Wheeler aligner \[[@R26]\], resulting in BAM files per sample \[[@R27]\]. Realignment around insertions and deletions (indels), and recalibration of quality scores, were performed with the GENOME ANALYSIS TOOLKIT \[[@R28]\]. Variant calling was conducted with the ATLAS2 suite \[[@R29]\], and this was followed by variant annotation as implemented in the CASSANDRA annotation suite. Individual variant files were subsequently merged into a project-level file to generate a genotype matrix of all identified variants.

Initial exclusion criteria for variant calls were as follows: variant posterior probability of \< 0.95, \< 3 variant reads, variant read ratio of \< 0.1, variant reads in a single strand direction, and total coverage of \< 6 or \> 1024 reads. Called variants that passed quality control in at least one individual were included in the project-level variant file. In total, 31 540 variants were identified in 1495 individuals with sequencing data available (897 DVT patients and 598 controls). We subsequently performed additional filtering with VCFTOOLS \[[@R30]\] to identify high-quality variants, requiring a sequencing depth of ≥ 10 reads, a call rate of ≥ 80%, a Phred score of ≥ 30, and Hardy--Weinberg equilibrium *P* \> 1.0 × 10^--4^ in the controls separately per study. A total of 20 054 variants passed quality control.

Statistical analysis {#S10}
--------------------

We conducted single-variant association analyses for 3617 low-frequency and common variants, defined as a minor allele frequency (MAF) of ≥ 1%, by using logistic regression as implemented in PLINK \[[@R31]\]. We calculated effect estimates as odds ratios (ORs) with corresponding 95% confidence intervals (CIs) per risk allele copy, and adjusted for sex, age, (study) origin, carriership of FV Leiden per allele copy, and carriership of PT G20210A. We assumed that X-chromosomal loci undergo complete inactivation. Linkage disequilibrium (LD) between variants was assessed in Europeans from the 1000 Genomes Project \[[@R32]\]. To identify secondary associations, we performed conditional analyses by adjusting for the lead variant at a locus (defined as region within 1 Mb of the lead variant). The Bonferroni threshold for significance was set at 1.38 × 10^--5^ (0.05 divided by 3617 variants) to account for multiple testing. We additionally calculated false discovery rates (FDRs), and variants with a FDR of \< 0.10 were carried forward for replication.

Rare variants (MAF ≤ 1%) were collapsed per gene and analyzed with the T1 burden test and the Sequence Kernel Association Test (SKAT) \[[@R33]\], the latter allowing differential effect directions. In total, we analyzed 16 188 variants in 647 genes with a cumulative minor allele count (cMAC) of \> 5. Analyses were adjusted for sex, age, (study) origin, and carriership of FV Leiden and PT G20210A. In the burden test, we used adaptive permutations to calculate empirical *P*-values, which were stratified by northwestern versus southern European origin. We calculated FDRs to take multiple testing into account. To identify which rare variant contributed to an association signal, we excluded one variant at a time and repeated the analyses. The gene-based association tests were performed with the PLINK/SEQ suite.

Replication {#S11}
-----------

Novel associations between common and low-frequency variants and DVT (FDR *\<* 0.10) were examined in metaanalysis data from the INVENT consortium. Details of the meta-analysis and the included studies are provided elsewhere \[[@R11]\]. In short, GWAS data from 12 studies, including 7507 VT patients and 52 632 controls, were meta-analyzed with an inverse-variance weighting fixed-effects model. It is of note that there was a small amount of overlap in VT patients *(N =* 384) between the discovery and the replication analyses, as some patients were also included in the meta-analysis of the INVENT consortium.

Results {#S12}
=======

Targeted DNA sequencing was successfully performed in 897 DVT patients and 598 controls. The study population characteristics are shown in [Table 1](#T1){ref-type="table"}. In total, 20 054 high-quality variants were identified, of which 11 268 were singletons (median of seven singletons per person; interquartile range of 4--10). An overview of the functional classes and the MAF distribution is shown in [Fig. S1](#SD1){ref-type="supplementary-material"}. The majority of the variants were rare and mapped to protein-coding sequences (*N =* 10 131), including several stop-loss and stop-gain variants. We also observed 168 indels and 530 splice variants. In addition, we identified a total of 5210 variants that had not been reported in any database.

Single-variant association analyses {#S13}
-----------------------------------

We tested 3617 low-frequency and common variants for an association with DVT risk. The quantile-quantile plot of the observed *P*-values versus the expected distribution is shown in [Fig. S2](#SD1){ref-type="supplementary-material"}. Statistically significant associations at the Bonferroni threshold were observed for 12 variants in four loci: *ABO, FGA--FGG, CYP4V2--KLKB1--F11,* and *F5* ([Table 2](#T2){ref-type="table"}). All four loci harbor established genetic risk factors for VT. Interestingly, only three of the 12 variants mapped to coding sequences. The exclusion of recurrent VT patients in a sensitivity analysis resulted in similar associations with DVT risk ([Table S3).](#SD1){ref-type="supplementary-material"} The lead variant in *ABO* was the well-known risk variant rs8176719 (frameshift variant; risk allele frequency \[RAF\] of 45%), encoding non-O blood groups. C-carriers had a 1.9-fold (95% CI 1.61--2.24) increased DVT risk per allele copy. The intronic *ABO* variant rs4962040 also reached statistical significance (RAF 59%, OR 1.53, 95% CI 1.28--1.83), although this association was diminished upon conditioning on rs8176719 (OR~adjusted~ 1.12, 95% CI 0.88--1.41). Likewise, none of the other 22 *ABO* variants was associated with DVT risk conditional on rs8176719 ([Table S4](#SD1){ref-type="supplementary-material"}). In *CYP4V2--KLKB1--F11,* the lead variant was intronic *F11* variant rs2036914 (RAF 60%, OR 1.65, 95% CI 1.38--1.97), which has been linked to increased FXI levels and VT \[[@R34],[@R35]\]. Three additional variants were associated with DVT risk at the Bonferroni threshold, one of which remained associated upon conditioning on rs2036914 (rs3733402 in KLKB1, OR~adjusted~ 1.33, 95% CI 1.08--1.64). Conditioning on a second known F11 risk variant (rs2289252) did not materially change this association (OR~adjusted~ 1.36, 95% CI 1.10--1.69). The *KLKB1* missense variant (p.Ser143Asn) leads to reduced binding of prekallikrein to its cofactor high molecular weight kininogen \[[@R36]\], affecting the initiation of the intrinsic coagulation cascade. In the *FGA--FGG* locus, the association with DVT was driven by missense *FGA* variant rs6050 (RAF 39%, OR 1.66, 95% CI 1.37--2.02) and downstream *FGG* variant rs2066865 (RAF 35%, OR 1.60, 95% CI 1.33--1.92), which have both been linked to increased γ′-fibrinogen levels and VT risk \[[@R37],[@R38]\]. rs6050 and rs2066865 were in high LD (*r*^2^ = 0.90), and reciprocal conditional analysis showed that they represented the same association signal ([Table S5](#SD1){ref-type="supplementary-material"}). We did not identify additional associations after conditioning on the lead variants ([Table S4](#SD1){ref-type="supplementary-material"}). Four intronic *F5* variants were associated with DVT risk at the Bonferroni threshold, were in almost complete LD (the lowest *r*^2^ between any pair was 0.90), and represented the same association signal. Carriers of the lead variant (rs6672595, RAF 76%) had a 1.6-fold increased DVT risk (95% CI 1.29--1.92) per risk allele. The variants were also in high LD (*r*^2^ = 0.77) with *F5* missense variant rs4524, for which an association with VT independently of FV Leiden has been reported \[[@R39]\]. In our study, carriers of rs4524 (RAF 73%) had a 1.3-fold higher DVT risk (95% CI 1.11--1.60) per allele copy, which was attenuated with adjustment for lead variant rs6672595 (OR~adjusted~ 1.10, 95% CI 0.74--1.63). On the other hand, the association between rs6672595 (and its proxies) and DVT risk remained, albeit with wider CIs, with adjustment for rs4524 ([Table S6](#SD1){ref-type="supplementary-material"}). No secondary association signals were observed in the *F5* region ([Fig. S3](#SD1){ref-type="supplementary-material"}).

In addition, we observed 50 variants that did not exceed the Bonferroni threshold for statistical significance, but did have low FDRs (\< 0.10). Almost all of these mapped to the four main loci and did not represent new association signals ([Table S7](#SD1){ref-type="supplementary-material"}). We additionally identified two novel, suggestive variant associations with DVT risk ([Table 3](#T3){ref-type="table"}). In *MASP1*, we observed an association with DVT for 3′-UTR variant rs72549167 (RAF 1.6%, FDR 9%). Carriers of the risk allele had a 3.5-fold increased DVT risk (95% CI 1.62--7.67) per allele copy. *MASP1* encodes mannan-binding lecture serine peptidase 1, which is involved in the lectin pathway of complement activation and has crosslinks with the clotting cascade \[[@R40],[@R41]\]. In particular, when activated by thrombin and activated platelets \[[@R42]\], *MASP1* can cleave several coagulation factors, including PT, thrombin-activatable fibrinolysis inhibitor, and FXIII \[[@R41]\]. Of the other 16 *MASP1* variants, one was also associated with DVT risk ([Table S8](#SD1){ref-type="supplementary-material"}), and was in complete LD with rs72549167. The other novel variant mapped to a synonymous variant in *CBS*, encoding cystathionine β-synthase, and was associated with DVT risk with an allelic OR of 1.31 (95% CI 1.11--1.55, FDR 9%). Cystathionine β-synthase catalyzes the conversion of homocysteine to cystathionine, and specific genetic defects in *CBS* lead to homocystinuria, a disorder that has been linked to increased VT risk \[[@R43]\]. We observed two additional common variants in *CBS*, not associated with rs1801181, and neither of these was associated with DVT risk ([Table S9](#SD1){ref-type="supplementary-material"}). We next aimed to replicate the two novel variant associations by using the meta-analysis data from the INVENT consortium, which included 7507 VT patients and 52 632 controls ([Table 3](#T3){ref-type="table"}). There was no clear evidence for an association of DVT with rs72549167 in *MASP1* (OR 1.21, 95% CI 0.96--1.52) or with rs1801181 in *CBS* (OR 1.00, 95% CI 0.96--1.05).

Gene-based association analyses {#S14}
-------------------------------

The impact of 16 188 rare variants mapping to 647 genes (cMAC ≥ 5) on DVT risk was assessed with aggregation tests. The results from the SKAT-based joint analyses of all rare variants per gene did not provide support for an association between rare variants and DVT risk. The most suggestive association signal was observed for *F2RL2 (P =* 0.0013, FDR 60%), encoding proteinase-activated receptor (PAR)-3. The burden tests identified one gene suggestive of an association with DVT risk. DVT patients had a burden of rare variants in *KLK5* (*P* = 0.0003, FDR 21%), which encodes a serine protease named kallikrein-related peptidase 5 and is involved in inflammatory responses through the PAR-2 system \[[@R44]\]. Of the 10 rare variants identified in *KLK5*, including five singletons, 26 variant alleles were observed in DVT patients as compared with three alleles in controls. All 10 variants mapped to protein-coding sequences. None of the variants was solely driving the association signal (data not shown).

Discussion {#S15}
==========

To identify novel genetic risk factors for DVT that have been missed by GWAS, we sequenced the coding regions of 734 genes related to hemostasis in 899 DVT patients and 599 controls. Our targeted sequencing approach confirmed several established risk loci. Specifically, lead variants at *ABO, FGA--FGG* and *CYP4V2--KLKB1--F11* have all previously been implicated in VT risk, both directly and via proxy variants \[[@R11]*--*[@R13],[@R19],[@R34]*--*[@R36]\]. The effect sizes observed in our study were slightly higher than those in earlier reports, which may, in part, be explained by our selection of individuals without a cancer diagnosis or recent surgery. Differences in genetic effects on PE versus DVT could also have played a role, in line with the so-called 'FV Leiden paradox' \[[@R45]\]. Although we did not discover novel risk loci, the secondary risk loci identified at *F5* and *CYP4V2--KLKB1--F11* may provide leads for a better understanding of the biological mechanism underlying these loci.

Interestingly, almost all associated variants mapped to non-coding sequences, whereas our sequencing design mainly targeted coding variation. In *F5* and *CYP4V2--KLKB1--F11,* there was little evidence that the (lead) associations could be explained by linkage to common, coding variants. This may point to non-coding variation as a causal risk factor, potentially influencing DVT risk by affecting gene regulation. Four co-inherited intronic variants in *F5,* which have not been implicated in VT risk, were associated with DVT risk at the Bonferroni threshold. Missense *F5* variant rs4524, which is an established risk variant independent of FV Leiden \[[@R38]\] and is in moderate LD with the associated *F5* variants, did not attain a high level of statistical significance in our study. Furthermore, its effect on DVT risk was strongly diminished after adjustment for our lead *F5* variant (rs6672595). Both variants are part of a large, strongly linked cluster of variants that spans across several introns and exons of *F5.* Additional fine-mapping in a large study is necessary to uncover the most likely causal variant. Another notable finding was the suggestive, secondary association signal at *CYP4V2--KLKB1--F11,* i.e. missense *KLKB1* variant rs3733402, which remained associated with DVT risk with an allelic OR of 1.4 after adjustment for rs2036914 and rs2289252. We are not the first to report an association signal at *CYP4V2--KLKB1--F11* secondary to rs2289252 and rs2036914 \[[@R11],[@R34]\], although the previously reported variants are not in LD with rs3733402, suggesting that this locus may indeed harbor multiple causal variants. In addition, we were unable to disentangle the effects of *FGA* rs6050 and *FGG* rs2068865 on DVT risk, owing to their strong, although imperfect, linkage. However, a previously reported haplotype analysis did not show an independent association with VT for the haplotype carrying *FGA* rs6050 \[[@R36]\].

In addition to the associations at the known loci, we identified two variants that have not been linked to VT risk, with low FDRs but association tests that did not pass the Bonferroni threshold. These were a synonymous variant in *CBS* and a 3'-UTR variant in *MASP1.* Neither variant, however, was replicated in the meta-analysis data from the INVENT consortium. Imputation quality was sufficient and there was no evidence of statistical heterogeneity. We cannot rule out the possibility that differences in the discovery and the replication study populations, e.g. owing to the inclusion of DVT patients versus patients with any VT event, could have explained the lack of replication. Alternatively, the associations in the discovery analysis might have been chance findings, taking into account the FDR of 9% for both variants.

The gene-based analyses did not support the hypothesis of a burden of rare, mainly coding variants in hemostasis-related genes contributing to DVT risk. We observed a potential association for a burden of rare variants in *KLK5,* with 26 alleles being observed in DVT patients as compared with three alleles in controls, although the FDR was relatively high (21%). The lack of significant gene associations may be explained by our limited sample size. Gene-based analyses for complex diseases generally require large study sizes, given the probably modest effect sizes and the expected proportion of causal variants \[[@R46]\]. Therefore, we might have missed associations between genes with rare variants and DVT risk. We also did not distinguish between rare variants with or without a predicted deleterious consequence, as advocated by some \[[@R46],[@R47]\], because this would have further increased the multiple testing burden and lowered cMACs. As the effects of VT on fitness are limited, we also did not expect strong purifying selection on deleterious variants. In addition, our group has previously reported an association between DVT and a burden of rare coding variants in *ADAMTS13* (17 alleles in DVT patients as compared with four alleles in controls, *N =* 192 individuals) \[[@R19]\]. In the present study, we observed a nominal association for a burden of rare variants in *ADAMTS13* with DVT risk (*P* = 0.048, 84 alleles in DVT patients as compared with 42 alleles in controls). Although the majority of studied rare *ADAMTS13* variants mapped to coding sequences (75%), the inclusion of non-coding variants may explain the difference in the results of the burden analyses. However, when we focused only on rare coding variants in *ADAMTS13,* we observed a similar association with DVT risk (*P* = 0.066, 55 alleles in DVT patients as compared with 27 alleles in controls). Larger studies are needed to elucidate the role of rare coding and non-coding variants in *ADAMTS13* in DVT risk.

The major limitation of our study is its limited sample size, which prevented us from detecting associations across the entire allele frequency spectrum. Given the multicausal nature of DVT, estimates of genetic effects on DVT risk are expected to be modest, requiring an even larger sample size. We attempted to maximize our statistical power by studying genetic variation in biologically plausible genes in a well-characterized study population. Specifically, we selected genetically enriched DVT patients, without some of the major clinical risk factors. In addition, we oversampled VT patients who had developed a recurrence and are therefore more likely to carry genetic risk variants. Except for a small number of patients with recurrent VT, we selected individuals not carrying FV Leiden and PT G20210A, and could therefore not study these variants or those in strong LD. Another limitation is the lack of generalizability of our findings to non-European populations. In addition, by design, our targeted sequencing approach did not allow us to study variation in regulatory regions outside our target area or variation in genes not previously linked to the hemostatic system. Therefore, we were unable to identify variants in untargeted regions of the candidate genes or novel DVT-associating genes outside the hemostatic system, or to assess variation in the recently identified risk loci *SLC44A2* and *TSPAN15* \[[@R11]\].

In conclusion, our targeted sequencing approach confirmed the association of several of the established VT risk loci. The secondary loci identified at *F5* and *CYP4 V2--KLKB1--F11* suggest that the underlying biological mechanism might be more complex than initially thought. In addition, we did not find evidence of a burden of rare variants in hemostasis-related genes affecting DVT risk.
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###### 

Study population characteristics

                                                                 DVT patients   Controls
  -------------------------------------------------------------- -------------- -------------
  *N*                                                            897            598
  Age (years), mean (SD)                                         48.1 (13.7)    47.1 (13.3)
  Male sex, *n* (%)                                               449 (50.1)     277 (46.3)
  Northwestern European origin, *n* (%)                           599 (67.8)     300 (50.2)
  DVT only, *n* (%)                                               755 (84.2)    NA
  PT G20210A carriers[\*](#TFN2){ref-type="table-fn"}, *n* (%)    15 (1.67)     NA
  FVL carriers[\*](#TFN2){ref-type="table-fn"}, *n* (%)           75 (8.36)     NA

DVT, deep vein thrombosis; FVL, factor V Leiden; NA, not applicable; PT, prothrombin; SD, standard deviation.

These formed part of a subgroup of 241 DVT patients who had a recurrence during follow-up in MEGA and THE-VTE study (prevalences of FVL and PT G20210A in that subgroup of 31.1% and 6.2%, respectively).

###### 

Associations between common variants and first deep vein thrombosis (*P* \< 1.38 × 10^--5^ )

  rsID            Chromosome   Position    Class        Gene      A~1~/A~2~   RAF     Discovery analysis   Conditional analysis[\*](#TFN4){ref-type="table-fn"}                       
  --------------- ------------ ----------- ------------ --------- ----------- ------- -------------------- ------------------------------------------------------ ------------------- -------
  rs3766110       1            169515183   Intronic     *F5*      C/A         0.774   1.54 (1.27−1.86)      1.07 × 10^−5^                                         NA                  NA
  rs3766111       1            169515204   Intronic     *F5*      C/T         0.773   1.57 (1.29−1.91)      6.82 × 10^−6^                                         NA                  NA
  rs3766113       1            169515307   Intronic     *F5*      G/A         0.770   1.55 (1.28−1.88)      8.59 × 10^−6^                                         NA                  NA
  **rs6672595**   1            169515536   Intronic     *F5*      T/C         0.757   1.58 (1.29−1.92)      6.11 × 10^−6^                                         NA                  NA
  **rs6050**      4            155507590   Missense     *FGA*     T/C         0.393   1.66 (1.37−2.02)      2.33 × 10^−7^                                         NA                  NA
  Rs2066865       4            155525276   Downstream   *FGA*     G/A         0.352   1.60 (1.33−1.92)      4.86 × 10^−7^                                         1.36(0.81--2.31)    0.245
  rs3733402       4            187158034   Missense     *KLKB1*   G/A         0.573   1.55 (1.30−1.86)      1.27 × 10^−6^                                         1.33 (1.08--1.64)   0.006
  rs4253399       4            187188094   Intronic     *F11*     T/G         0.458   1.50 (1.27−1.76)      8.34 × 10^−7^                                         1.16 (0.90--1.49)   0.246
  rs3822057       4            187188152   Intronic     *F11*     A/C         0.545   1.44 (1.23−1.70)      6.74 × 10^−6^                                         0.91 (0.62--1.35)   0.642
  **rs2036914**   4            187192481   Intronic     *F11*     T/C         0.602   1.65 (1.38−1.97)      2.47 × 10^−8^                                         NA                  NA
  **rs8176719**   9            136132908   Frameshift   *ABO*     T/TC        0.451   1.90 (1.61−2.24)     1.39 × 10^−14^                                         NA                  NA
  rs4962040       9            136133531   Intronic     *ABO*     G/A         0.594   1.53 (1.28−1.83)      3.67 × 10^−6^                                         1.12 (0.88--1.41)   0.355

A~1~, reference allele; A~2~, risk allele; CI, confidence interval; NA, not applicable; OR, odds ratio; RAF, risk allele frequency. Single-variant association analyses for 3617 low-frequency and common variants (minor allele frequency of \> 1%) were conducted with logistic regression on the assumption of an additive mode of inheritance. Analyses were adjusted for sex, age, (study) origin, carriership of factor V Leiden per copy of the risk allele, and carriership of prothrombin G20210A.

We conducted conditional logistic regression analyses in which we adjusted for the lead variant per locus (highlighted in bold, i.e. *F5* rs6672595, *FGA* rs6050, *F11* rs2036914, and *ABO* rs8176719).

###### 

Novel variant associations with deep vein thrombosis (false discovery rate \[FDR\] \< 0.10) and replication effort

               Discovery analysis   Replication                                                                                                             
  ------------ -------------------- ------------- ------------ --------- ----- ------- ------------------ ------- ------ ------- ------------------ ------- -------------
  rsl801181    21                   44480616      Synonymous   *CBS*     G/A   0.370   1.31 (1.11−1.55)   0.002   0.09   0.364   1.00 (0.95−1.05)   0.926   0.96 (0.02)
  rs72549167    3                   186952375     3'-UTR       *MASP1*   C/G   0.016   3.52 (1.62−7.67)   0.002   0.09   0.010   1.21 (0.96−1.52)   0.102   0.86 (0.12)

A~1~, reference allele; A~2~. risk allele; Cl. confidence interval; OR. odds ratio; RAF. risk allele frequency; SD. standard deviation; UTR. untranslated region. Discovery analysis was performed with logistic regression on the assumption of an additive mode of inheritance. Analyses were adjusted for sex. age. (study) origin, carriership of factor V Leiden per copy of the risk allele, and carriership of prothrombin G20210A. Replication analysis was performed on data from the INVENT consortium. Genome-wide association study results from 12 studies were meta-analyzed with a fixed-effect meta-analysis model based on inverse-variance weighting. Heterogeneity was assessed by use of Cochran's *Q* statistic and the *12* index. For rslSO 1181. we observed a *Q*-value of 8.69. an *I*2-value of 0.00. and a *P*-value of 0.65. For rs72549167, we observed a *Q*-value of 9.06. an *I*2-value of 0.00. and a *P*-value of 0.62.

###### Essentials

-   Deep vein thrombosis (DVT) has a large unknown genetic component.

-   We sequenced coding areas of 734 hemostasis-related genes in 899 DVT patients and 599 controls.

-   Variants in *F5, FGA-FGG, CYP4V2-KLKB1-F11,* and *ABO* were associated with DVT risk.

-   Associations in *KLKB1* and *F5* suggest a more complex genetic architecture than previously thought.
